Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.62 |
| ▸ | PI4KA | P42356 | 10/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580610 | 0.80 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.78 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8069211 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2342091 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16949893 | 0.77 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9074153 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11908593 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1357265 | 0.77 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1868819 | 0.77 | FDPS (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16949944 | 0.77 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108605844-A | A kind of method that Jiading garlic stem apex detoxic seedling forms detoxification clove | 上海惠和种业有限公司 | 2018-10-02 | — | — | CN | claimed |
| CN-105669751-B | The preparation of acyclonucleosides acid phosphoramide types compound and its salt and the application in anti-virus aspect | 洛阳聚慧医药科技有限公司 | 2018-09-21 | — | — | CN | claimed |
| CN-106565785-A | Nucleoside phosphoramidate type compound with HBV/HIV resistance activity and salt and application of nucleoside phosphoramidate type compound | 周雨恬 | 2017-04-19 | — | — | CN | claimed |
| CN-105669751-A | Preparation of non-cyclic nucleotide phosphoamides and salts thereof and application of non-cyclic nucleotide phosphoamides and salts thereof in aspect of antivirus | 洛阳聚慧医药科技有限公司 | 2016-06-15 | — | — | CN | claimed |
| US-8039611-B2 | 2′-hydroxyl group-modified ribonucleoside derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-10-18 | — | — | US | claimed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-0689610-A1 | DNA SEQUENCING BY MASS SPECTROMETRY VIA EXONUCLEASE DEGRADATION | SEQUENOM, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0684979-A1 | LUBRICANT COMPOSITIONS CONTAINING COMPLEXES OF ALKOXYLATED AMINE, ACID, AND ADENINE. | EXXON RESEARCH ENGINEERING CO (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0670897-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE | ISIS PHARMACEUTICALS, INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994021822-A1 | DNA SEQUENCING BY MASS SPECTROMETRY VIA EXONUCLEASE DEGRADATION | SEQUENOM, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994019437-A1 | LUBRICANT COMPOSITIONS CONTAINING COMPLEXES OF ALKOXYLATED AMINE, ACID, AND ADENINE | EXXON RESEARCH & ENGINEERING COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1994008003-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE | ISIS PHARMACEUTICALS, INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5290460-A | Friction resistant compounds | EXXON RESEARCH & ENGINEERING CO. (US) | 1994-03-01 | — | — | US | disclosed |
| US-4704193-A | Covalently coupled cofactor modified electrodes and methods of synthesis and use | GTE LABORATORIES INCORPORATED (US) | 1987-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | ADORA2A 276/4885ADORA1 181/4885PI4KA 487/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | ADORA2A 828/4885ADORA1 1014/4885PI4KA 1526/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | ADORA2A 2246/4885ADORA1 1287/4885PI4KA 2441/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | ADORA2A 3858/4885ADORA1 3856/4885PI4KA 1271/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | ADORA2A 2670/4885ADORA1 2796/4885PI4KA 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.